Finacor is a medication generally used to address major lipid abnormalities, particularly in managing the clinical conditions of primary hypertriglyceridemia (excessively high triglycerides) and mixed dyslipidemia (a combination of high cholesterol and high triglycerides). Its therapeutic application relates to the management of systemic imbalance.

Therapeutic Use Summary

The primary therapeutic domain is managing severe elevations of triglycerides, which is intended to assist in reducing the risk of acute complications, such as pancreatitis, and assists in the management of complex fat imbalances (high LDL-C, low HDL-C) that plays a role in managing long-term cardiovascular risk factors. It is commonly used to help with managing these lipid abnormalities in conditions like Type 2 Diabetes or Metabolic Syndrome.

Quick Fact: Supportive Lipid Management This medication is applied across domains where additional support is needed, helping to address chronic, elevated blood fats.

Regulatory References

1. FENOFIBRATE tablet - DailyMed - NIH

Finacor (Fenofibrate) is subject to strict eligibility rules as defined by government regulatory authorities, primarily focusing on organ function and specific health conditions.

Contraindicated Populations (Must Not Use)

Finacor is formally contraindicated in several patient groups, meaning it must not be used:

• Patients with severe renal impairment (including those receiving dialysis).
• Patients with active liver disease (including primary biliary cirrhosis).
• Patients with pre-existing gallbladder disease.
• Nursing mothers.
• Those with a known hypersensitivity to fenofibrate or a history of photoallergy to fibrates.

Eligibility by Age and Condition

Population Group	Official Eligibility Status (Regulatory Labeling)
Adults (18+)	Approved for use in this population.
Children/Adolescents	Not recommended; safety and efficacy have not been established (use in this group is restricted).
Older Adults (Geriatric)	Generally allowed, but dose selection must be based on an assessment of renal function.
Mild-to-Moderate Renal Impairment	Use is restricted and requires a lower-strength formulation or dosage reduction.
Pregnancy	Use is conditional; permitted only if the potential benefit justifies the potential risk to the fetus.
Secondary Hyperlipidemia	Conditions like uncontrolled Type 2 Diabetes or hypothyroidism must be adequately treated before initiation of Finacor is considered.

Finacor Interactions with other medicines and products

The interaction profile for Finacor (fenofibrate) is defined by officially documented risks of additive toxicity and specific constraints on co-administration with other medicines. The primary regulatory cautions involve combinations that can increase exposure risks or enhance side effects, as stated in government drug labels.

Documented Pharmacodynamic and Exposure Risks

Interacting Product Category	Official Interaction Outcome	Regulatory Note
Statins (HMG-CoA Reductase Inhibitors)	Increased risk of Myopathy and Rhabdomyolysis (additive muscle toxicity).	Risk is heightened in the elderly and those with renal failure or diabetes.
Coumarin Anticoagulants (e.g., Warfarin)	Potentiation of the anticoagulant effect, leading to a prolongation of Prothrombin Time/INR.	Requires monitoring of INR/PT upon co-administration.
Immunosuppressants (e.g., Cyclosporine)	Consideration of increased risk of nephrotoxicity.	Caution advised due to potential for renal impairment.

Timing and Substance Constraints

Bile-Acid Binding Resins (e.g., Cholestyramine) impede the absorption of fenofibrate, potentially reducing drug exposure. Regulatory documents mandate timing separation: Finacor must be administered at least 1 hour before or 4 to 6 hours after the resin. The official guidance notes that excessive alcohol consumption should be limited, as it is associated with an increased risk of pancreatitis.

Modulating Lipid Metabolism at the Genetic Level

The mechanism of Finacor is centered on its active metabolite, fenofibric acid, which acts as a ligand for the nuclear receptor Peroxisome Proliferator-Activated Receptor Alpha ( PPARalpha). This interaction modulates gene expression involved in lipid processing within the liver and other key metabolic tissues. Fenofibric acid acts as an agonist, turning on genes that enhance fatty acid breakdown while suppressing genes, such as Apolipoprotein C-III ( ApoC-III), that naturally inhibit fat clearance. This genomic modulation leads to a sustained reduction in the liver’s production and secretion of triglyceride-rich particles, which results in altered blood lipid concentrations.

Accelerating Triglyceride Clearance and Turnover

By increasing the expression of the enzyme Lipoprotein Lipase ( LPL), the drug significantly enhances the capacity of the body to hydrolyze and remove circulating triglycerides carried in very-low-density lipoproteins ( VLDL) and chylomicrons. This accelerated systemic catabolism of fat particles, coupled with reduced hepatic synthesis, results in the modulation of blood lipid turnover.

Regulating HDL Components and Lipoprotein Structure

The PPARalpha mechanism also promotes the production of Apolipoproteins A-I and A-II ( ApoA-I/A-II), the primary structural components of High-Density Lipoprotein ( HDL). The resulting increase in HDL concentration supports reverse cholesterol transport. Furthermore, the drug alters the biochemical composition of other lipoproteins, causing a structural shift in low-density lipoprotein ( LDL) particles.

How Finacor is Used in Clinical Practice

Finacor (Fenofibrate) is administered via the oral route exclusively, using the available tablet or capsule forms. The usage pattern is defined by a once-daily schedule for the long-term management of high blood lipids.

---

Administration and Dosing Principles

Usage Principle	General Guidelines Summary
Dosing Range	Typical doses for adults range from 105 mg to 160 mg once daily, depending on the specific formulation and indication. Dosage adjustments are usually made at 4- to 8-week intervals based on lipid responses.
Intake Condition	Administration requirements are formulation-dependent: some forms must be taken with meals to ensure optimal absorption, while other specific tablet forms may be taken independent of food.
Physical Handling	Tablets and capsules must be swallowed whole and should not be crushed, broken, or chewed, as these actions may alter the drug's release properties.

---

Use Protocol and Adjustments

Finacor is intended for long-term use as an adjunct to diet. The selection of the starting dose and the maintenance regimen accounts for the patient's renal function. For individuals with mild to moderate renal impairment, standard protocols indicate a reduced initial dose (e.g., 40 mg or 48 mg once daily). For patients who must also take a bile acid binding resin, Finacor is typically taken at least 1 hour before or 4 to 6 hours after the resin. Standard practice suggests that if a daily dose is missed, the next scheduled dose should be taken at the usual time and two doses should not be taken to compensate.

Research Evidence / Overview of Studies for Finacor

This overview summarizes the available research evidence for Finacor (fenofibrate), focusing on the types of studies conducted, the outcomes measured, and what remains uncertain, based on official regulatory and scientific literature.

---

Evidence for Managing Severely High Triglycerides

Research for this indication involved randomized, placebo-controlled trials that studied adults presenting with exceptionally high blood triglyceride (TG) levels (typically ge 500 mg/dL) over short intervals. Studies focused on changes in TG levels and related lipid markers. These trials described patterns related to changes in triglyceride measurements, which is a biomarker change monitored in these studies. Evidence concerning the effect on the rare complication of pancreatitis is not derived from direct, large-scale event-rate trials. Long-term outcomes are not fully established and data on sustained durability remains limited.

---

Evidence for Primary Hypercholesterolemia and Mixed Dyslipidemia

Research included randomized trials that evaluated fenofibrate alone and as an add-on to other common lipid-regulating treatments in adults with primary high cholesterol or mixed dyslipidemia. The studies monitored changes across the entire lipid profile, including measurements of LDL-C, total cholesterol, and HDL-C. Findings described measurements showing an increase in the HDL-C and changes in other harmful lipid fractions. Data related to long-term cardiovascular events in the general dyslipidemia population is considered mixed and heterogeneous.

---

Evidence for High-Risk Cardiovascular Outcomes in Type 2 Diabetes

Extensive research came from large-scale, long-term, randomized outcome trials (MACE trials) that monitored major outcomes, including the occurrence of non-fatal heart attacks and strokes, in large cohorts of adults with Type 2 Diabetes over follow-up durations of up to five years. When looking at the primary outcome of Major Adverse Cardiovascular Events (MACE) across the entire diabetic population studied, the findings were mixed. The evidence does describe patterns related to a lower occurrence of microvascular complications, such as the reduced need for laser treatment for diabetic retinopathy. Subgroup findings are considered hypothesis-generating and require further confirmation.

Key Studies & References

1. Fenofibrate - StatPearls - NCBI Bookshelf (Summary of FDA/Efficacy Data and Indications)

Common questions about Finacor (FAQ)

---

Q: How quickly should I expect to see results after starting Finacor?

A: According to official product information, a healthcare provider typically assesses how well Finacor is working by measuring blood lipid levels. Dosage adjustments are usually based on these lab results, which are generally checked at 4- to 8-week intervals during the initial treatment period. This clinical time frame is often used by healthcare providers to assess initial effectiveness and measurable changes.

Q: Can Finacor cause weight gain?

A: Weight gain is not listed as one of the most common side effects of Finacor in regulatory documents. However, it has been mentioned in some postmarketing or less frequent reports, meaning its exact incidence is not well established. Concerns about changes in weight should always be discussed with a healthcare professional.

Q: Is it normal to feel a little dizzy when you first start taking Finacor?

A: Official information indicates that dizziness is listed as a common adverse reaction associated with Finacor use, occurring in 1% to 10% of patients during clinical trials. As a common adverse reaction, this effect is frequently observed, especially when initiating treatment.

Q: Does Finacor interact with common over-the-counter pain relievers like ibuprofen?

A: Finacor may increase the amount of ibuprofen (a type of nonsteroidal anti-inflammatory drug or NSAID) in the blood. This potential increase in concentration could affect the way ibuprofen works. If considering an over-the-counter pain reliever while using Finacor, discussing potential drug interactions with a healthcare provider is recommended.

Q: Can people with diabetes safely take Finacor?

A: Finacor has been included in large-scale studies with patients who have Type 2 diabetes mellitus. Official guidance states that if hyperlipidemia is secondary to uncontrolled diabetes, the diabetes must be adequately managed before starting Finacor. This indicates the medication is commonly studied and prescribed for patients with Type 2 diabetes when appropriate criteria are met.

Q: Is Finacor known to affect sleep patterns?

A: Official product information lists insomnia (difficulty sleeping) as a common adverse reaction, occurring in 1% to 10% of patients. Any changes in sleep patterns should be reported to a healthcare provider.

Q: What happens if I miss a dose of Finacor?

A: The official instructions for Finacor administration are clear: if a dose is forgotten, the patient should not take two doses to compensate for the missed one. The patient should simply take the next scheduled dose at the usual time.

Q: Is there a generic version of Finacor available?

A: Yes, the active ingredient in Finacor, Fenofibrate, is widely available as a generic prescription drug. Generic Fenofibrate is available and is the chemically identical active ingredient.

Q: What's the best time of day to take Finacor?

A: Finacor is prescribed to be taken as a single dose, once daily. The specific instructions on whether it needs to be taken with or without food depend on the exact formulation prescribed. Patients should follow the specific timing and food instructions provided by their prescriber for their specific formulation.

Q: Can Finacor be crushed or split if I have trouble swallowing pills?

A: No. Official guidance states that Finacor tablets and capsules must be swallowed whole. They should not be crushed, broken, or chewed because doing so can alter the way the drug is released in the body and affect its effectiveness.

Q: Does Finacor interact with birth control pills?

A: There is no direct regulatory information indicating that Finacor affects the effectiveness of oral contraceptive pills. However, official guidance advises that women who are able to become pregnant should use effective contraception during treatment. The topic should be discussed with a healthcare professional.

Q: Is Finacor safe for women who are not pregnant but are of child-bearing age?

A: Finacor is approved for use in adults, including women of child-bearing age. However, because its use during pregnancy is conditional, official documents state that women who are able to become pregnant should use effective contraception throughout the treatment period.

Q: Is a slightly elevated heart rate normal when taking Finacor?

A: While not listed among the most common effects, fast heartbeat has been mentioned in less frequent postmarketing reports associated with Finacor use. Changes in heart rate should be mentioned to a healthcare provider for proper evaluation.

Q: Is Finacor safe for people with a history of stomach ulcers?

A: Gastrointestinal discomfort is a common side effect, and rare adverse event reports have mentioned peptic ulcer. A patient's full medical history, including any history of stomach ulcers, is necessary for a prescribing doctor to weigh potential risks.

Q: Can I take Finacor if I'm already taking a blood thinner?

A: Finacor can increase the effect of certain blood thinners like warfarin, which are known as coumarin anticoagulants. This may raise the risk of bleeding. If Finacor is prescribed alongside such a blood thinner, the anticoagulant dosage will require reduction, and blood clotting levels (INR/PT) must be monitored closely.

Q: Can Finacor affect mood or cause anxiety?

A: Official information lists anxiety and depression among the less frequent psychiatric side effects reported during postmarketing surveillance. Any changes in mood or mental state should be brought to the attention of a healthcare team.

Q: Does Finacor make me more sensitive to the sun?

A: Yes, official product information includes photosensitivity (increased sensitivity of the skin to sunlight) as a less common side effect. Using sun protection is a common precaution related to photosensitivity.

Q: Why is blood pressure monitoring important while on Finacor?

A: While Finacor's primary function is to regulate lipids, studies indicate it may influence blood pressure in some individuals. Some reports suggest that both increases and decreases in blood pressure have occurred. Monitoring blood pressure is a standard practice when taking cardiovascular medications.

Q: Can Finacor be used to treat a heart rhythm disorder?

A: No. The official indication for Finacor is to be used alongside diet to treat high blood lipids—specifically high triglycerides and high cholesterol. It is not approved or indicated for the treatment of heart rhythm disorders.

Q: How do I know if Finacor is working for me?

A: The effectiveness of Finacor is officially determined by the periodic measurement of serum lipid levels (blood fat tests). If blood tests do not show an adequate improvement in lipid levels after a review period, alternative management strategies are typically discussed.

Q: What is the strength (dosage) that most people start on for Finacor?

A: For one common formulation used to treat high cholesterol and mixed dyslipidemia, the typical dose is 105 mg once daily for adults. The precise dose prescribed is determined by the healthcare provider based on the individual's condition and physical status.

Official Storage and Disposal Requirements

Finacor must be stored strictly according to its official regulatory label to ensure product stability and safety. The mandated conditions are:

Requirement	Official Statement
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not freeze or refrigerate.
Protection	Keep in the original, tightly closed container. Protect from both light and moisture.
Child Safety	Keep Finacor out of the sight and reach of all children.
Disposal	Dispose of unused or expired Finacor only through a drug take-back program or authorized collection site. Do not flush the medication down the toilet or pour it into a drain.

These official rules define how the product must be stored and discarded, ensuring its quality until the expiration date and preventing environmental contamination.